Updated treatment and prevention guidelines for pertussis

Journal of the American Academy of Physician Assistants

Volumn 27, Issue 1, 2014, Pages 19-25

  Cohen, Sara ^a   Black, Aliza ^a   Ross, Alexis ^a   Mandel, Ellen D ^a  

^a PACE UNIVERSITY   (United States)

Author keywords

DTaP; guideline; pertussis; Tdap; whooping cough

Indexed keywords

ANTIINFECTIVE AGENT; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ARTICLE; HUMAN; IMMUNIZATION; PERTUSSIS; PRACTICE GUIDELINE; UNITED STATES;

ANTI-BACTERIAL AGENTS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; WHOOPING COUGH;

EID: 84892369077     PISSN: 15471896     EISSN: 08937400     Source Type: Journal    
DOI: 10.1097/01.JAA.0000438528.61644.91     Document Type: Article

References (46)

1. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis. 2003: 3:413-418
2. Lai FY, Thoon KC, Ang LW, et al. Comparative seroepidemiology of pertussis, diphtheria, and poliovirus antibodies in Singapore: Waning pertussis immunity in highly immunized population and the need for adolescent booster doses. Vaccine.2012;30(24):3566-3571
3. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR. 2002;51:73-76
4. Centers for Disease Control and Prevention. Guidelines for the control of pertussis outbreaks. February 2006. http://www.cdc. gov/pertussis/outbreaks/ index.html. Accessed October 8, 2012
5. Cherry JD. Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367(9):785-787
6. Pertussis. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington DC: Public Health Foundations, 2012. http://www. cdc.gov/vaccines/pubs/pinkbook/pert.html. Accessed November6, 2012
7. Bechini A, Tiscione E, Boccalini S, et al. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): A review of evidences and recommendations. Vaccine. 2012;30(35):5179-5190
8. Centers for Disease Control and Prevention. Pertussis (whooping cough). Fast Facts. August 28, 2013. http://www.cdc.gov/ pertussis/fast-facts.html. Accessed October 15, 2013
9. Centers for Disease Control and Prevention. Pertussis epidemic - Washington, 2012. MMWR. 2012;61(28):517-522
10. Cornia PA, Lipsky B. Microbiology, epidemiology, and pathogenesis of Bortadella pertussis infection. http://www. uptodate.com/contents/microbiology- epidemiology-and-pathogenesis-of-bordetella-pertussis-infection. Accessed April 14, 2013
11. Brooks DA, Clover R. Pertussis infection in the United States:role for vaccination of adolescents and adults. J Am Board Fam Med. 2006;19(6):603-611
12. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 18(2):326-382
13. Paisley, RD, Blaylock J, Hartzell JD. Whooping cough in adults:an update on a reemerging infection. Am J Med.2012;125(2):141-143
14. Cortese MM, Baughman AL, Brown K, Srivastava P. A "new age" in pertussis prevention new opportunities through adult vaccination. Am J Prev Med. 2007;32(3):177-185
15. Centers for Disease Control and Prevention. Guidelines for the Control of Pertussis Outbreaks. Atlanta, GA, 2000. http://www. cdc.gov/pertussis/ outbreaks/guide/index.html. Accessed October8, 2012
16. California Department of Public Health. Pertussis: Laboratory Testing. Richmond, CA. February 2011. http://www.cdph. ca.gov/programs/immunize/ Documents/PertussisLaboratoryTesting. pdf. Accessed October 18, 2013
17. Lind-Brandberg L, Welinder-Olsson C, Lagergård T, et al. Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections. J Clin Microbiol.1998;36(3):679-683
18. Centers for Disease Control and Prevention. Pertussis: Diagnosis Confi rmation. June 2012. http://www.cdc.gov/pertussis/clinical/ diagnostic-testing/ diagnosis-confi rmation.html. Accessed December 8, 2012
19. Cherry JD, Grimprel E, Guiso N, et al. Defining pertussis epidemiology clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005;24(5):S25-S34
20. Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents, and adults: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(6):817-840
21. Okada K, Komiya T, Yamamoto A, et al. Safe and effective booster immunization using DTaP in teenagers. Vaccine.2010;28(48):7626-7633
22. Child Catch-up. http://www.vaccines.gov/who and when/child/ index.html#. Accessed November 25, 2012
23. Camenga DR, Kyanko K, Stepczynski J, et al. Increasing adult Tdap vaccination rates by vaccinating infant caregivers in the pediatric offi ce. Acad Pediatr. 2012;12(1):20-25
24. Mooi FR, van Loo IH, van Gent M, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerging Infect Dis. 2009;15(8):1206-1213
25. Lomurray K, Sander M. Using the North Dakota Immunization Information System to determine adolescent vaccination rates and uptake. Public Health Rep. 2011;126 Suppl 2:78-86
26. Weston W, Messier M, Friedland LR, et al. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine. 2011;29(47):8483-8486
27. Pertussis: Summary of Vaccine Recommendations. http://www. cdc.gov/vaccines/vpd-vac/pertussis/recs-summary.htm. Accessed November 6, 2012
28. Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix):results of two randomized trials. Vaccine. 2012;30(9):1721-1728
29. Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep. 1991;40(RR-10):1-28
30. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(41):1424-1426
31. Fortner KB, Kuller JA, Rhee, EJ, Edwards KM. Infl uenza and tetanus, diphtheria, and acellular pertussis vaccinations during pregnancy. Obstet Gynecol Surv. 2012;67(4):251-257
32. Novella S. Whooping cough epidemic. http://www.sciencebasedmedicine. org/index.php/whooping-cough-epidemic/. Accessed April 5, 2013
33. Lavine JS, King AA, Bjørnstad ON. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc Natl Acad Sci USA. 2011;108(17):7259-7264
34. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med. 2013;368(6):583-584
35. Committee on Infectious Diseases, American Academy of Pediatrics. Pertussis (whooping cough). In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. Elk Grove Village, IL, 2012:553-556. http://aapredbook.aappublications.org/content/1/ SEC131/SEC237.body. Accessed October 14, 2013
36. Centers for Disease Control and Prevention. Pertussis (whooping cough) postexposure antimicrobial prophylaxis. August 2013.http://www.cdc.gov/ pertussis/outbreaks/PEP.html. Accessed October 18, 2013
37. von König C-HW. Use of antibiotics in the prevention and treatment of pertussis. Pediatr Infect Dis J. 2005;24(5),S66-S68
38. Tiwari T, Murphy TV, Moran J. National immunization program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep. 2005;54(RR-14):1-16
39. Langley J, Halperin S, Boucher FD, Smith B. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics. 2004; 114(1): e96-101
40. Lebel MH, Mehra S. Effi cacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: A prospective, random ized, single blind trial. Pediatr Infect Dis J. 2001:20(12):1149-1154
41. Cooper WO, Griffi n MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med. 2002;156(7):647-650
42. Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-defi cient pop u la tion [abstract]. Rev Infect Dis. 1987;9 Suppl 2:S218-S229
43. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev.2007;(3):CD004404
44. Sawyer M. ACIP Pertussis Vaccine Work Group. Pertussis Vaccine Work Group Update. 2012. http://www.cdc.gov/ vaccines/acip/meetings/meetings-info.html. Accessed November26, 2013
45. Centers for Disease Control. Recommended immunization schedules for persons aged 0 through 18 years - United States, 2012. MMWR. 2012;61(5):1-4. http://cdc.gov/mmwr/preview/ mmwrhtml/mm6105a5.htm. Accessed October 10, 2013
46. Advisory Committee on Immunization Practices (ACIP)Recommended Immunization Schedule for Adults Aged 19 Years and Older-United States, 2013. MMWR. 2013;62(1):9-19.http://www.cdc.gov/mmwr/preview/mmwrhtml/su6201a3.htm. Accessed October 11, 2013